References in periodicals archive ?
IURTC's technology covers the use of next-generation, parenteral gentamicin derivatives as antimicrobial agents with the potential for reduced toxicity.
La Jolla also entered into a second option agreement with IURTC and the University of Alabama at Birmingham for the use of these next-generation compounds for the treatment of certain rare genetic diseases, such as cystic fibrosis and Duchenne muscular dystrophy.
In conjunction, La Jolla has signed a second option agreement with IURTC and the University of Alabama at Birmingham (UAB) for the use of these next-generation compounds for the treatment of certain rare genetic diseases, such as cystic fibrosis and Duchenne muscular dystrophy.
"This partnership is another way for IURTC to help move technologies along the development process," said IURTC President Tony Armstrong.
is now an equity investor in BehNeem LLC, the Indianapolis company created to develop the exclusively licensed Epsilen Environment technology from IURTC.
(IURTC)is a not-for-profit agency that facilitates industry-Indiana University research and technology collaborations.
Consisting of five divisions, IURTC operates from offices in Indianapolis and Bloomington.
Acronyms browser ?
Full browser ?
- Iurkevich, Pamfil
- Iurkevich, Pamfil Danilovich
- Iurkovskii, Fedor
- Iurkovskii, Fedor Nikolaevich
- Iurkunas, Vitautas
- Iurovskaia, Rimma
- Iurovskaia, Rimma Iakovlevna
- Iurovskii, Iurii Ilich
- Ius gladii
- Ius patronatus
- Ius Sanguinis
- Ius soli
- Ius soli
- Iushkevich, Vasilii
- Iushkevich, Vasilii Aleksandrovich
- Iushkov, Serafim